
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences Inc is experiencing a positive outlook due to promising biomarker and safety data, which may enhance investor confidence before the final 12-month data for PMN310. The advancing clinical development of PMN267 demonstrates a strong selectivity profile, indicating potential for significant disease-modifying activity across multiple neurodegenerative conditions, including ALS and frontotemporal dementia. Additionally, the favorable Phase 1a results for PMN310, including its safety and dose-linear pharmacokinetics, support its clinical progression and validate the approach of targeting toxic oligomers in neurodegenerative diseases.
Bears say
ProMIS Neurosciences faces a negative outlook primarily due to several key financial and operational risks. The company may encounter difficulties with slower-than-anticipated market uptake, attributed to heightened competition and potential partnership risks that could hinder its growth trajectory. Additionally, there exists a looming risk of near-term dilution, which could adversely impact shareholder value amidst concerns regarding the fundamental disease correlation of their target therapies.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares